The Immune Response Corporation (IMNR), a biopharmaceutical company, will begin enrolling patients in Italy in a Phase I/II study investigating IR103, the company’s newest product candidate for the treatment of HIV.

The randomised, double blind, comparative, multi-centre Phase I/II study will begin this year and last for 52 weeks. The primary objective is to evaluate safety and bioactivity, or the ability to generate HIV-specific immune responses to IR103, in HIV patients who have not initiated highly active anti-retroviral therapy (HAART), claims a company release.

Remune and IR103 are in clinical development by IMNR and are not approved by any regulatory agencies in any country at this time.

IMNR is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS).